{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:02:17Z","timestamp":1780923737673,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009243","name":"Direction G\u00e9n\u00e9rale de l\u2019offre de Soins","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009242","name":"Direction generale de l'offre de soins","doi-asserted-by":"publisher","award":["PHRC-N 18-0251"],"award-info":[{"award-number":["PHRC-N 18-0251"]}],"id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.resmer.2026.101266","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:35:16Z","timestamp":1774600516000},"page":"101266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-3455","authenticated-orcid":false,"given":"Bruno","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-366X","authenticated-orcid":false,"given":"Carole","family":"Plan\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7860-1880","authenticated-orcid":false,"given":"Arnaud","family":"Chambellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2885-8757","authenticated-orcid":false,"given":"Anne","family":"Charloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Degano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1577-6595","authenticated-orcid":false,"given":"Thomas","family":"Gille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Gl\u00e9rant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-3461","authenticated-orcid":false,"given":"St\u00e9phane","family":"Jouneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4526-8129","authenticated-orcid":false,"given":"Nathan","family":"Mewton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-7347","authenticated-orcid":false,"given":"Hilario","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-9318","authenticated-orcid":false,"given":"Thierry","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1512-0115","authenticated-orcid":false,"given":"G\u00e9raldine","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Traclet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5894-4491","authenticated-orcid":false,"given":"S\u00e9gol\u00e8ne","family":"Turquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-8158","authenticated-orcid":false,"given":"Yvonne","family":"Varillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4962-6680","authenticated-orcid":false,"given":"Lidwine","family":"Wemeau-Stervinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-7812","authenticated-orcid":false,"given":"Sophie","family":"Yavordios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-3859","authenticated-orcid":false,"given":"Camille","family":"Amaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2026.101266_bib0001","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.resmer.2026.101266_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2026.101266_bib0003","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(25)00129-8","article-title":"Global epidemiology and burden of interstitial lung disease","volume":"13","author":"Spagnolo","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0004","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0005","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0006","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: molecular mechanisms and potential clinical applications in lung disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resmer.2026.101266_bib0007","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2026.101266_bib0008","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","article-title":"Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis","volume":"14","author":"Paterniti","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resmer.2026.101266_bib0009","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces Respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0011","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0012","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2026.101266_bib0013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.rmed.2019.08.002","article-title":"Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: results from the INPULSIS and INPULSIS-ON trials of nintedanib","volume":"156","author":"Richeldi","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106722","article-title":"Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study","volume":"191","author":"Adams","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305429","article-title":"Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis","volume":"19","author":"Sugino","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.resmer.2026.101266_bib0016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Investigators IT. Nintedanib with add-on Pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"25","key":"10.1016\/j.resmer.2026.101266_bib0017","first-page":"00355","article-title":"Nintedanib combined with Pirfenidone in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis: a long-term retrospective multicentre study (Combi-PF)","volume":"S0300-2896","author":"Meersseman","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.resmer.2026.101266_bib0018","first-page":"100948","article-title":"OrphaLung network. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version","volume":"83","author":"Cottin","year":"2023","journal-title":"Respir Med Res"},{"key":"10.1016\/j.resmer.2026.101266_bib0019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-021-01714-y","article-title":"Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis","volume":"22","author":"Belhassen","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resmer.2026.101266_bib0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1513\/AnnalsATS.202404-430RL","article-title":"Persistence of antifibrotic therapy in patients with idiopathic Pulmonary Fibrosis: a Pulmonary Fibrosis Foundation patient registry study","author":"Kulkarni","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resmer.2026.101266_bib0021","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s12325-023-02454-9","article-title":"A narrative review of real-world data on the safety of Nintedanib in patients with idiopathic pulmonary fibrosis","volume":"40","author":"Podolanczuk","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.resmer.2026.101266_bib0022","doi-asserted-by":"crossref","first-page":"00084","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resmer.2026.101266_bib0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.resinv.2021.04.005","article-title":"Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: a multicenter retrospective observational study in Japan","volume":"59","author":"Hisata","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.resmer.2026.101266_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00230-2018","article-title":"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2026.101266_bib0025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1183\/09031936.00198013","article-title":"Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis","volume":"45","author":"Ogura","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2026.101266_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01060-2018","article-title":"No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone","volume":"53","author":"Richeldi","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2026.101266_bib0027","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0028","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive Pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0029","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0030","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resmer.2026.101266_bib0031","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMp1500526","article-title":"Forced vital capacity in idiopathic pulmonary fibrosis\u2013FDA review of pirfenidone and nintedanib","volume":"372","author":"Karimi-Shah","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0032","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0033","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Investigators IT. Nintedanib in progressive fibrosing interstitial Lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2026.101266_bib0034","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041226000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:12:25Z","timestamp":1780920745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041226000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"alternative-id":["S2590041226000206"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101266","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2026.101266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101266"}}